Saturday, July 21, 2018 1:50:50 PM
I am a new poster here. I've had a long history with NNVC stock starting back in 2008. I was heavily long and got out around 1.15 at the end of 2015. So I missed the recent rally. Over the time I owned the stock I took out some decent gains mostly as a result of technical analysis. My worst moves were motivated by my "fundamental analysis".... mostly buying into the hype of management. I exited because I lost faith in management's ability to execute and the whole thing about there being two classes of stock with the insiders owning the good stock... I think they are called the B shares.
My understanding is the company is just focused on one product now for ocular herpes infections. If they can deliver on that one the stock will
be fine. I got tired of Gene Seymour's failure to meet one milestone after another. The insiders have a sweet deal with their preferred B shares but the common holders could wind up getting very diluted while the insiders reap most of the rewards.
Technically the stock hit strong resistance that was predicted for the 3.30 to 3.50 zone. Volume analysis shows that the selling pressure picked up strongly starting the 22nd of March. There is strong support in the 1.50 to 1.65 range and I would expect the decline not to exceed that. This a normal pull-back after the strong trend we have had since early January."
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM